PL3503890T3 - Stosowanie pridopidyny w leczeniu dystonii - Google Patents

Stosowanie pridopidyny w leczeniu dystonii

Info

Publication number
PL3503890T3
PL3503890T3 PL17844432.9T PL17844432T PL3503890T3 PL 3503890 T3 PL3503890 T3 PL 3503890T3 PL 17844432 T PL17844432 T PL 17844432T PL 3503890 T3 PL3503890 T3 PL 3503890T3
Authority
PL
Poland
Prior art keywords
pridopidine
dystonia
treatment
Prior art date
Application number
PL17844432.9T
Other languages
English (en)
Inventor
Michael Hayden
Spyridon Papapetropoulos
Juha-Matti Savola
Eli Eyal
Beth Borowsky
Igor D. Grachev
Mark Forrest Gordon
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3503890T3 publication Critical patent/PL3503890T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17844432.9T 2016-08-24 2017-08-24 Stosowanie pridopidyny w leczeniu dystonii PL3503890T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
PL3503890T3 true PL3503890T3 (pl) 2025-03-24

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17844432.9T PL3503890T3 (pl) 2016-08-24 2017-08-24 Stosowanie pridopidyny w leczeniu dystonii

Country Status (12)

Country Link
US (2) US11826361B2 (pl)
EP (1) EP3503890B1 (pl)
JP (2) JP7278210B2 (pl)
CN (1) CN110012661A (pl)
AU (1) AU2017315781B2 (pl)
BR (1) BR112019003731A2 (pl)
CA (1) CA3035099C (pl)
DK (1) DK3503890T3 (pl)
ES (1) ES3009437T3 (pl)
MX (1) MX2019002190A (pl)
PL (1) PL3503890T3 (pl)
WO (1) WO2018039475A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
CN115551505B (zh) * 2020-05-04 2026-03-17 普瑞尼亚神经治疗有限公司 使用选择性s1r激动剂治疗病毒性感染、疾病或病症
KR20250121149A (ko) * 2022-12-27 2025-08-11 프리레니아 뉴로테라퓨틱스 엘티디. 소아 헌팅턴병 치료를 위한 프리도피딘
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
JP2008501749A (ja) * 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
PE20160195A1 (es) * 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
HRP20251431T1 (hr) 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Also Published As

Publication number Publication date
JP7278327B2 (ja) 2023-05-19
CA3035099C (en) 2023-01-17
DK3503890T3 (da) 2025-01-27
EP3503890A4 (en) 2020-05-06
AU2017315781A1 (en) 2019-04-11
US20240075021A1 (en) 2024-03-07
JP2019524897A (ja) 2019-09-05
ES3009437T3 (en) 2025-03-26
US20190192496A1 (en) 2019-06-27
CA3035099A1 (en) 2018-03-01
AU2017315781B2 (en) 2021-01-28
EP3503890A1 (en) 2019-07-03
JP2021119189A (ja) 2021-08-12
WO2018039475A8 (en) 2018-10-04
BR112019003731A2 (pt) 2019-07-16
EP3503890B1 (en) 2024-12-18
JP7278210B2 (ja) 2023-05-19
CN110012661A (zh) 2019-07-12
MX2019002190A (es) 2019-09-11
US12564582B2 (en) 2026-03-03
US11826361B2 (en) 2023-11-28
WO2018039475A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
IL269371A (en) Treatment methods
IL257105A (en) Modified cells and methods of therapy
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3551285A4 (en) DEFIBRILLATOR
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
PL3265053T3 (pl) Sposoby leczenia skóry
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
EP3564335A4 (en) SURFACE TREATMENT AGENT
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3474802T3 (da) Medicinsk forbinding
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
DK3778595T3 (da) Pancreatitisbehandling
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
DK3231444T3 (da) Ny behandling
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
IL251904A0 (en) Apilimod for use in the treatment of melanoma
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego